IOM laser: Surgical Optimizing of a Middle Ear Implant (MET )With Laser Velocimetry in Patients With Moderate to Severe Hearing Loss in Case of Failure of Conventional Equipment

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Completed
CT.gov ID
NCT02845115
Collaborator
(none)
2
2
17.9

Study Details

Study Description

Brief Summary

The aging of the population, and greater exposure to noise, are responsible for an increased incidence of hearing loss (presbycusis). This hearing loss is sensorineural disability that has become a real public health problem. The main means of rehabilitation of this disability is represented by the apparatus of patients with conventional hearing aids. However, these hearing aids have several drawbacks that limit their profits, often abandoning the prosthesis by the patient.

Middle ear implants were developed to answer these problems. They are intended to amplify the sound signal by transmitting directly to the middle ear to compensate for the hearing loss and are indicated in case of failure or contraindication of conventional equipment. However, these middle ear implants currently have limitations as performance failure. Recent data show that the performance of the ossicles repair techniques are dependent on the coupling of the ossicular prosthesis to the ossicles. Furthermore, advances in the understanding of the biomechanics of the ossicles confirm the importance of the placement and linkage of surgical restoration processes. This data can be applied to middle ear implants to improve performance. Indeed, a preliminary experimental study on anatomical parts, using analysis of the vibration of the middle ear structures by laser velocimetry, allowed the investigators to define the transducer placement method and coupling method to ossicles.

Investigators wish to validate in vivo results in a pilot study on a small number of patients by comparing two surgical techniques guided by velocimetric measures.

Condition or Disease Intervention/Treatment Phase
  • Device: Conventional implantation
  • Device: optimized implantation with laser velocimetry
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
2 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Pilot Study Evaluating Surgical Optimizing of a Middle Ear Implant (MET )With Laser Velocimetry in Patients With Moderate to Severe Hearing Loss in Case of Failure of Conventional Equipment
Study Start Date :
Feb 1, 2014
Actual Primary Completion Date :
Feb 1, 2015
Actual Study Completion Date :
Aug 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Other: control

standard care : usual technique for implanting

Device: Conventional implantation
Usual implantation technique of a middle ear implant. The principle of the ossicular stimulator middle ear transducer MET 7000 (Middle Ear Transducer, METTM) is to directly transmit sounds on the ossicles bypassing the outer ear. Their constraint is the surgical placement of the implant. MET 7000 system (OTOLOGICS LLC, USA) is the implant that the investigators will use for their patients. The stimulator is usually placed against the body of the anvil by simple contact in the case of sensorineural hearing loss. In the case of mixed hearing loss, the stimulator will come in contact with the bracket using a titanium clip (ossicular prosthesis used in otologic surgery for ossiculoplasties). The optimized version corresponds to the use of the conventionally used in mixed deafness and applied to neurosensory deafness art. It is screwed onto the mastoid bone, the motor is suspended in the mastoid cavity and transmits vibrations to the body of the anvil by simple contact of the transducer.

Experimental: laser velocimetry

optimized implantation of laser velocimetry

Device: optimized implantation with laser velocimetry
Other Names:
  • Group benefiting from the implantation technique optimized by laser velocimetry of a middle ear implant.( the MET ossicular stimulator 7000 the company "Otologics LLC")
  • Outcome Measures

    Primary Outcome Measures

    1. Change from Baseline hearing at 8 months post-implantation (hearing gain), measured by tone and speech audiometry [at baseline (day 0) and 8 months]

      The hearing will be measured by tone and speech audiometry in silence and in noise (dB) Results will be averaged per patient.

    Secondary Outcome Measures

    1. Number of surgical implantation performed for the surgical laser velocimetry optimization technique [at 14 months]

      number of surgical implantations performed in the required conditions and, if necessary, deviations will be described.

    2. description of adverse events throughout the study [pre and post-operatively at day 0, at day 4, day 8 and then at 2, 3, 4, 5, 6, 7, 8 and 14 months.]

    3. Middle ear transfer function measured by laser velocimetry [pre-operatively at day 0 and then at 2, 3, 8 and 14 months.]

      measured in mm/s/Pa

    4. Tone and speech audiometry in silence and in noise (dB) [Baseline at inclusion visit, day 0, and then at 2, 3, 4, 5, 6, 7, 8 and 14 months.]

    5. Change in the quality of life measured by GHSI (Glasgow Health Status Inventory) score [day 0, and 2, 3, 5, 8 and 14 months.]

      Changes will be described in both groups. GHSI questionnaire appreciate the impact of hearing loss on quality of life and whose translation is adapted to the French context.

    6. Change in the quality of life measured by GBI (Glasgow Benefit Inventory) score [day 0, and 2, 3, 5, 8 and 14 months.]

      Changes will be described in both groups. GBI questionnaire appreciate the benefit of the port of hearing aid before surgery and the benefit of the middle ear implant after the surgery.

    7. Change in the quality of life measured by APHAB ( Abbreviated Profile of Hearing Aid Benefit) score [day 0, and 2, 3, 5, 8 and 14 months.]

      Changes will be described in both groups. APHAB questionnaire is validated in subjects deaf to assess the discomfort associated with deafness in conditions of erveday life.

    8. Change in the quality of life measured by SSQ (Speech Saptial Qualiteies) score [day 0, and 2, 3, 5, 8 and 14 months.]

      Changes will be described in both groups. SSQ questionnaire evaluate the binaural hearing.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age between 18 to 60 years;

    • Having given written informed consent prior to any procedure related to the study;

    • Covered by a Health System where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.

    • Indication and IOM implantation request by the patient with a patient physically, psychologically and legally able to ask its implementation

    • Average deafness to severe (mean thresholds between 40 to 90 dB) with speech discrimination> 40% to 75 dB.

    • Deafness of pure perception or mixed hearing loss

    • Non-fluctuating deafness over the last two years

    • Failed or cons-indication to conventional equipment

    • Rocky Scanner and MRI normal brain

    • Patient fluent in French (to ensure validity audiological measures

    Exclusion Criteria:
    • Pregnant women or likely to be during the study.

    • Not affiliated with a social security scheme Patients

    • Major Patients protected by provisions of the law (Public Health Code).

    • Refusal of consent.

    • Ongoing Participation in another study that may interfere with the proposed study (investigator assessment).

    • Existence of a cons-indication for surgery or port of the implant

    • Motivation only aesthetic, evaluated by the principal investigator.

    • Inability of predictable medium-term monitoring.

    • Acoustic neuroma, tumors and other evolutionary processes of the rock and the cerebellopontine angle.

    • Pathology requiring follow-up MRI (IOM against-indicating MRI).

    • Patient with against-indication to MRI.

    • Contraindication to the establishment of a pacemaker ossicular MET

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Hospices Civils de Lyon

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hospices Civils de Lyon
    ClinicalTrials.gov Identifier:
    NCT02845115
    Other Study ID Numbers:
    • 2011.679
    First Posted:
    Jul 27, 2016
    Last Update Posted:
    Aug 22, 2017
    Last Verified:
    Jul 1, 2016
    Keywords provided by Hospices Civils de Lyon
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 22, 2017